TXNDC13 Blocking Peptide
- Known as:
- TXNDC13 Blocking Peptide
- Catalog number:
- 33r-3629
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- TXNDC13 Blocking Peptide
Related genes to: TXNDC13 Blocking Peptide
- Gene:
- TMX4 NIH gene
- Name:
- thioredoxin related transmembrane protein 4
- Previous symbol:
- TXNDC13
- Synonyms:
- DJ971N18.2, KIAA1162, PDIA14
- Chromosome:
- 20p12.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-09-13
- Date modifiied:
- 2016-10-05
Related products to: TXNDC13 Blocking Peptide
Related articles to: TXNDC13 Blocking Peptide
- Melanoma is a highly metastatic and lethal malignancy originating from melanocytes. Disulfidptosis is a recently discovered type of programmed cell death with promising potential in cancer therapy. This study aims to establish a prognostic risk model based on disulfidptosis-related gene signatures and investigate their roles in melanoma progression. - Source: PubMed
Publication date: 2026/01/20
Yi YiTao RuiShi ZeqiChen LanZhu ZhanyongWu Min - Follicular atresia is a major determinant of ovarian failure in multiparous sows. Non-coding RNAs (ncRNAs) play an important role in the regulatory mechanisms controlling apoptosis within ovarian granulosa cells (GCs). - Source: PubMed
Publication date: 2025/07/17
Qin XinxinZhang JinbiYin ChaoLi FanLi WenjieCheng XiaolongDu XingLi QifaPan Zengxiang - The increasing prevalence of age-related macular degeneration (AMD), a disease that can result in the loss of central vision, is an emerging problem worldwide due to aging societies. Growing patient numbers create a challenge for the healthcare system. Understanding the mechanisms of AMD pathogenesis will aid in early, personalized, and efficient intervention, helping to mitigate this issue. Current diagnostic methods rely on optical coherence tomography and angiography imaging, which identify existing damages, but do not provide information on the mechanisms behind them. In the present work, we demonstrate a difference in the serum RNA profile between neovascular AMD (nAMD) patients and controls. Moreover, the RNA profile of nAMD patients corresponded with anatomical changes in the retinal fluid compartments as well as atrophic changes of the retina. We followed two independent ways to control false positive leads, and when these approaches were combined, thioredoxin-related transmembrane protein 4 (TMX4) was observed to be differentially expressed by both approaches. This finding opens a new pathway in AMD studies, which are limited due to restricted access to live human target material and the limited value of animal models of human AMD. - Source: PubMed
Publication date: 2025/05/19
Heloterä HannaKostanek JoannaLiukkonen MikkoSiintamo LeeaLinna-Kuosmanen SuviWatala CezaryBlasiak JanuszKaarniranta Kai - Thiol isomerases regulate the thiol-disulfide exchange of functional proteins in cells. Using genetically modified mouse models and inhibitors, we and others demonstrated that 7 thiol isomerases (ERp57, protein diisulfide isomerase, ERp72, ERp46, ERp5, TMX4, and TMX1) participate in thrombosis. There are 21 thiol isomerases in mammals, but whether other enzymes of this family also contribute to thrombosis remains unknown. - Source: PubMed
Publication date: 2025/02/27
He ChaoYang AizhenLv KeyuZhang YuxinZhao ZhenzhenLu YiFang ChaoHan YueWu DepeiJiang MiaoZhang JingyuWu Yi - Vascular thiol isomerases (VTIs) encompass proteins such as protein disulfide isomerase (PDI), endoplasmic reticulum protein 5 (ERp5), ERp46, ERp57, ERp72, thioredoxin-related transmembrane protein 1 (TMX1), and TMX4, and play pivotal functions in platelet aggregation and formation of thrombosis. Investigating vascular thiol isomerases, their substrates implicated in thrombosis, the underlying regulatory mechanisms, and the development of inhibitors targeting these enzymes represents a rapidly advancing frontier within vascular biology. In this review, we summarize the structural characteristics and functional attributes of VTIs, describe the associations between these enzymes and thrombosis, and outline the progress in developing inhibitors of VTIs for potential antithrombotic therapeutic applications. - Source: PubMed
Publication date: 2025/02/17
Jiang LongguangYuan CaiFlaumenhaft RobertHuang Mingdong